This medication is used across two primary therapeutic domains: supportive management of chronic systemic hypertension and assists with symptoms associated with benign prostatic hyperplasia (BPH) in men.

---

Understanding Therapeutic Benefits

The medication is commonly used to help manage high blood pressure, a condition characterized by periods of systemic imbalance due to persistently high pressure. By addressing these elevated pressures, it provides supportive therapeutic benefit that may help reduce the physiological strain on the heart and blood vessels. Additionally, it is applied in clinical settings to address symptom clusters that interfere with daily functioning, such as difficulty starting urination, a weak stream, or frequent, urgent trips to the bathroom associated with BPH. It may contribute to improved comfort by easing these distressing manifestations.

“The medication is generally relevant when supportive symptom management is appropriate across domains involving heightened systemic burden.”

Quick Fact: Supports Management of Urinary Flow Disturbances (It assists with maintaining functional stability in situations where patients experience urinary flow disturbances.)

Regulatory References

1. U.S. National Library of Medicine DailyMed

Cardura (Doxazosin) is a prescription medicine approved for use in adults for managing hypertension and symptoms of Benign Prostatic Hyperplasia (BPH). Eligibility is defined by specific regulatory criteria concerning age, concurrent conditions, and patient physiological status.

Official Eligibility Constraints

Category	Eligibility Status
Approved Population	Adults (Hypertension and BPH); Elderly patients (use is acceptable); Patients with renal impairment (no dose change required).
Not Recommended	Children and adolescents (safety/efficacy not established); Patients with severe hepatic impairment (lack of clinical experience).
Contraindicated	Known hypersensitivity to doxazosin or other quinazolines; BPH patients with concomitant hypotension or certain urinary tract obstructions (e.g., anuria, overflow bladder); Patients with specific gastrointestinal narrowing (for extended-release form only).

Conditional Use and Restrictions

• Liver Function: Use with caution is required for patients with mild or moderate hepatic impairment.
• Prostate Screening: The label requires prostate cancer to be ruled out prior to commencing BPH treatment, as symptoms can overlap.
• Cataract Surgery: Patients must inform the eye surgeon of current or past doxazosin use due to the potential risk of Intraoperative Floppy Iris Syndrome (IFIS).
• Pregnancy/Lactation: Use during pregnancy is only advised if the potential benefit outweighs the risk; some regulatory labels state use during breastfeeding is contraindicated.

Interactions with other medicines and products

Official regulatory information describes specific interaction patterns for Doxazosin, relating primarily to pharmacodynamic effects and the drug’s metabolism. The primary concern is the risk of additive blood pressure lowering when Doxazosin is co-administered with other medications that cause vasodilation or reduce blood pressure.

Product Category / Substance	Official Interaction Statement
PDE-5 Inhibitors (e.g., Sildenafil, Tadalafil)	Co-administration can result in additive hypotensive effects [FDA/EMA].
Other Antihypertensives / Alcohol	Concurrent use may increase the risk of hypotension due to additive pharmacodynamic effects [NIH/EMA].
Strong CYP3A4 Inhibitors	Doxazosin is primarily metabolized by CYP3A4, and co-administration with strong inhibitors (e.g., Ketoconazole, Ritonavir) requires caution due to potential for increased systemic exposure [FDA].
Cimetidine	Administration of Cimetidine resulted in a documented 10% increase in the mean Area Under the Curve (AUC) of immediate-release Doxazosin [EMA/FDA].

Population-Specific and Formulation Constraints

The interaction profile includes population-specific warnings and administration constraints. Use of the extended-release formulation is not recommended in patients with severe hepatic impairment. In patients with mild hepatic impairment, a single dose of the immediate-release formulation resulted in a 40% increase in systemic exposure [FDA]. Furthermore, the official labeling dictates a timing rule that the extended-release formulation must be administered once daily with breakfast [FDA]. While food does not cause a clinically significant reduction in absorption for the immediate-release tablet, drugs that decrease gastrointestinal motility may increase the exposure of the extended-release formulation.

How Cardura works

Cardura (doxazosin) works by acting as a selective competitive antagonist of post-synaptic alpha-1 (alpha1) adrenergic receptors. This action affects two primary physiological systems where these receptors are abundant: the vascular smooth muscle and the smooth muscle of the lower urinary tract.

---

Modulation of Vascular Alpha-1 Adrenoceptors

This domain involves Cardura's binding to alpha1-receptors on the vascular smooth muscle lining the walls of arterioles and veins. Normally, the binding of the natural neurotransmitter norepinephrine to these receptors triggers smooth muscle contraction, leading to vasoconstriction and increased systemic vascular resistance. By competitively blocking this binding, Cardura initiates a cascade that causes the vascular smooth muscle to relax, resulting in vasodilation. This physiological adjustment leads to a reduction in total peripheral resistance.

---

Regulation of Lower Urinary Tract Smooth Muscle Tone

This mechanistic domain targets the alpha1-receptors, particularly the alpha1A subtype, found in high density in the prostate capsule, prostatic stroma, and bladder neck. Activation of these receptors causes smooth muscle contraction in this region, which increases resistance to urinary outflow. Cardura’s antagonism of these receptors modulates this contractile pathway, promoting smooth muscle relaxation in the bladder neck and prostate. The resulting physiological consequence is a reduction in urethral resistance, leading to modified outflow dynamics.

How Cardura is Used

Cardura (doxazosin) is a prescription medicine administered exclusively via the oral route as a single, daily dose. The foundational principle for its use, for both managing hypertension and treating symptoms of benign prostatic hyperplasia (BPH), is gradual dose titration.

Treatment must begin with the lowest available dose, typically 1 mg once daily. Doses are incrementally increased, generally by doubling (to 2 mg, 4 mg, and 8 mg), at intervals of one to two weeks until the desired therapeutic response is achieved. The maximum daily dose for the immediate-release tablet for hypertension is 16 mg/day, while the extended-release form maximum is 8 mg/day.

---

Formulation-Specific Administration

Cardura is supplied in immediate-release (IR) tablets and extended-release (GITS) tablets. The administration instructions differ based on the form:

• IR Tablets: These may be taken once daily with or without food and can be administered in the morning or the evening.
• Extended-Release (GITS) Tablets: This form must be swallowed whole and should be taken with the morning meal (breakfast). To maintain the controlled release mechanism, this tablet must not be chewed, split, or crushed.

Population and Procedural Constraints

The standard adult titration schedule applies to older adults and those with renal impairment. However, Cardura is used with caution in patients with evidence of hepatic impairment due to the drug’s metabolism. The safety and effectiveness of doxazosin have not been established in pediatric patients, restricting its use to adults.

Research Evidence / Overview of Studies for Cardura

Evidence for use in Benign Prostatic Hyperplasia (BPH) Symptoms

This section will summarize the structure of the clinical evidence for the evaluation of Doxazosin in BPH symptoms, focusing on findings from short-term and intermediate-term randomized controlled trials (RCTs) and comprehensive systematic reviews.

Research explored Doxazosin's evaluation regarding symptoms associated with Benign Prostatic Hyperplasia (BPH), a condition where symptoms may vary in intensity. The main evidence comes from short-term randomized controlled trials (RCTs) in which men with moderate to severe symptoms received either Doxazosin or an inactive substitute (placebo). These studies were also extended by systematic reviews and long-term research examining Doxazosin when combined with other BPH treatments.

Primary Outcomes Studied in BPH Trials

Studies monitored patient-reported outcomes describing perceived discomfort, primarily using scales like the International Prostate Symptom Score (IPSS), and objective functional measures, such as Peak Urinary Flow Rate (Q max). Findings described patterns observed in the studies where groups receiving Doxazosin reported different measurements of symptom scores and flow rates measured during the study period compared to those receiving placebo.

However, the evidence highlights what is known and what is still uncertain. Some analyses of the clinical trial data suggest the average difference in measured symptom scores between the groups, compared to placebo, may be modest based on established clinical benchmarks. Furthermore, while studies monitored symptoms over the short-term (typically 14 to 16 weeks), there is limited information for long-term outcomes regarding the maintenance of these measured patterns when Doxazosin is used alone (monotherapy).

---

Evidence for use in Chronic Systemic Hypertension

This part will detail the types of studies that examined Doxazosin's role in managing high blood pressure, including large-scale comparative trials that positioned it against other established drug classes.

Doxazosin was also studied in relation to chronic systemic hypertension, a condition involving periods of heightened symptoms of physiological strain. Research includes standard placebo-controlled trials and larger, long-term comparative RCTs. One significant study, the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), was applied in research contexts involving fluctuating or unstable symptoms where Doxazosin was compared against other drug classes in high-risk patients.

Comparative Study Design and Context

These large comparative studies focused on high-risk hypertensive populations, including older adults (age 55 and over) with existing risk factors for heart disease. Research highlights measurements taken during the study period, indicating that the Doxazosin group achieved a measured reduction in blood pressure. Large comparative studies found that the group assigned to Doxazosin was associated with a higher incidence of combined cardiovascular disease events, specifically heart failure, compared to the diuretic comparator group. This finding led researchers to stop the Doxazosin arm of the trial early.

Key Studies & References

1. Doxazosin mesylate DailyMed - U.S. National Library of Medicine (NLM)
2. Doxazosin - MedlinePlus Drug Information (National Institutes of Health/NLM)

How to Store and Dispose of Cardura (Doxazosin)

Official regulatory guidelines define the mandatory requirements for storing and discarding Cardura tablets.

Storage Conditions

Cardura must be stored at a Controlled Room Temperature, typically maintained between 20°C and 25°C (68°F and 77°F).

• Protection: The tablets must be protected from excessive moisture and excess heat and should remain in the original, tightly closed container.
• Child Safety: It is strictly required that the medication be stored out of the sight and reach of children.

Disposal Instructions

Disposal of any unused or expired tablets must comply with local and national pharmaceutical waste regulations.

If a drug take-back program is unavailable and immediate disposal is necessary to prevent accidental ingestion, official guidelines permit flushing doxazosin tablets down the toilet.